

Exercise of the over-allotment option in the IPO of Linc

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

Skandinaviska Enskilda Banken AB (publ) ("**SEB**" or the "**Global Coordinator**") has today notified Linc AB (publ) ("**Linc**" or the "**Company**") and Bengt Julander (the "**Principal Shareholder**") that the over-allotment option has been exercised in full and that the stabilisation period has ended.

In connection with the initial public offering of Linc and the listing of the Company's shares on Nasdaq Stockholm on 28 May 2021 (the "Offering"), the Principal Shareholder granted the Global Coordinator an option to purchase an additional of up to 2,238,805 existing shares in Linc to cover any over-allotment in connection with the Offering (the "**Over-Allotment Option**"), exercisable in whole or in part within 30 days after the date on which Linc's shares commenced trading on Nasdaq Stockholm. The Over-Allotment Option has been exercised in full.

No price stabilisation activities have been carried out since the Offering, and due to the Company's share price performance SEB has, as stabilising manager, decided to end the stabilisation period.

Contacts

Karl Tobiesson, CEO +46 (0) 709358574 karl.tobieson@linc.se
Thomas Berg, CFO +46 (0) 72 231 45 00 thomas.bergh@linc.se
Johan Hähnel, Investor Relations +46 (0) 70 605 63 34 johan.hahnel@linc.se

This information is information that Linc AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-06-04 09:00 CEST.

About Linc

Linc invests in product oriented companies in the Nordic Life Science industry. We mainly invest in and develop small and medium-sized product oriented life science companies in Medical Technology and Pharmaceuticals. The investments are made in both private and public companies and in research and operational companies. Typically, investments in drug development take place in an early phase compared with investments in medical technology.

Linc is an active and long-term owner with a broad industrial network to support the portfolio companies. We work together with management, founders and the board to realize the inherent potential that exists in the company, have ambitious plans for further development and expansion and actively participate in the nomination committee's work. At the end of 2020, Linc had a NAV (net asset value) of about SEK 2,5 billion.

Important information

This press release is not an offer to sell or a solicitation of any offer to purchase or subscribe for any securities issued by Linc.

This announcement is not being made in and may not be distributed or sent into the United States, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. This press release does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

The securities described herein have also not been and will not be registered under the applicable securities laws of Australia, Canada or Japan and, subject to certain exemptions, may not be offered or sold in or into or for the account or benefit of any person having a registered address in, or located or resident in Australia, Canada or Japan. There will be no public offering of the securities described herein in Australia, Canada or Japan.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/ EC (and, with respect to the United Kingdom, such regulation as it forms part of the domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018) (the "**Prospectus Regulation**"). Linc has published a Swedish prospectus prepared pursuant to the Prospectus Regulation. The Swedish prospectus has been approved and registered by the Swedish Financial Supervisory Authority. Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the Swedish prospectus.

In any EEA member state other than Sweden, and in the United Kingdom, this press release is only addressed to and is only directed at qualified investors in that member state or the United Kingdom within the meaning of the Prospectus Regulation (as applicable), i.e., only to investors who can receive the offer without an approved prospectus in such EEA member state or in the United Kingdom.

In the United Kingdom, this document is only being distributed to and is only directed at (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**") or (ii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i) and (ii) above together being referred to as "**relevant persons**"). The shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person must not act or rely on this document or any of its contents. Persons distributing this document must satisfy themselves that it is lawful to do so.

Matters discussed in this press release may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe," "expect," "anticipate," "intend," "estimate," "will," "may," "continue," "should", "could" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond the Company's control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice.

Press Release
04 June 2021 09:00:00 CEST



Attachments

[Exercise of the over-allotment option in the IPO of Linc](#)